Total patients (antigen)
|
Sex; age range (median), years
|
Other neurological features or symptoms
|
CSF findings, range (median)
|
Typical “limbic” MRI abnormality
|
Cancer
|
Immunotherapy other than corticosteroids
|
Neurological outcome
|
Hu, n = 4; Ma2, n = 1; atypical, n = 1 | 5M, 1F; 28–65 (63) | Encephalomyelitis, n = 2; sensory neuronopathy, n = 3; 2 cerebellar/or brainstem, n = 2 | *WBC 0–81 (3); †Prot 74–150 (79) | Typical, n = 4; other, n = 2‡ | SCLC, n = 4; testicular, n = 1; thyroid, n = 1 | IVIg, n = 1; CTX, n = 2;IVIg+PEX +Rituximab+Aza, n = 1 | PI (Ma2), n = 1; stable (Hu), n = 1;died, n = 4 |
| | | | | | | |
nCMAg, n = 5 | 5F; 24–65 (44) | Diffuse encephalitis, n = 2; decreased level of consciousness and hypoventilation, n = 1; chorea/dystonia, n = 1 | WBC 15–49 (30); Prot 18–97 (67) | ‡Other, n = 4; normal, n = 1 | Teratoma, n = 3 (ovary, n = 2; thymus, n = 1); cancer of thymus, n = 1; no tumour, n = 1 | IVIg, n = 1; PEX, n = 1;IVIg+PEX, n = 1 | CI (n = 4, teratoma, n = 3, cancer of thymus, n = 1); deteriorated (no tumour), n = 1 |
| | | | | | | |
VGKC, n = 3 | 2M, 1F; 38–60 (58) | Peripheral nerve hyperexcitability, n = 1 | WBC 0–4 (2); Prot 45–79 (63) | Typical, n = 3 | Prostate, n = 1 | IVIg, n = 2 | CI, n = 2; stable, n = 1 |
| | | | | | | |
No antibodies, n = 3 | 1M, 2F; 28–60 (40) | Multiple (cerebellar myelopathy neuropathy), n = 1 | WBC 2–119 (10); Prot 32–132 (47) | Typical, n = 2; other, n = 1 | Prostate, n = 1 | Aza, n = 1 | CI, n = 3 |